SCHEMBL126839

SCHEMBL126839

O=C(O)CSC1CCC1SCC(=O)O

nearest known ligand 0.43

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.43
CYP2C19 P33261 2/20 0.43
HIF1A Q16665 1/20 0.43
ALDH1A1 P00352 3/20 0.35
L3MBTL1 Q9Y468 2/20 0.33
PKM P14618 1/20 0.33
PHGDH O43175 1/20 0.33
USP2 O75604 1/20 0.32
FFAR1 O14842 1/20 0.31
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17548382 0.90 CYP2D6 (0.46) CYP2D6CYP2C19HIF1AALDH1A1L3MBTL1
SCHEMBL20247784 0.85 CYP2D6 (0.32) CYP2D6CYP2C19HIF1A
SCHEMBL9277557 0.79 CYP2D6 (0.36) CYP2D6CYP2C19HIF1AALDH1A1
SCHEMBL31631322 0.78
SCHEMBL997207 0.78 CYP2D6 (0.43) CYP2D6CYP2C19HIF1AALDH1A1L3MBTL1
SCHEMBL9263490 0.77 TSHR (0.46) CYP2D6CYP2C19HIF1AALDH1A1USP2
SCHEMBL9259412 0.77 TSHR (0.50) CYP2D6CYP2C19HIF1AALDH1A1L3MBTL1
SCHEMBL9259410 0.77 TSHR (0.50) CYP2D6CYP2C19HIF1AALDH1A1L3MBTL1
SCHEMBL9263487 0.77 TSHR (0.46) CYP2D6CYP2C19HIF1AALDH1A1USP2
SCHEMBL19650564 0.76 ABCB1 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170369651-A1 CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO INSERT THERAPEUTICS, INC. 2017-12-28 US disclosed
US-20170362346-A1 METHODS AND SYSTEMS FOR POLYMER PRECIPITATION AND GENERATION OF PARTICLES CERULEAN PHARMA INC (US) 2017-12-21 US disclosed
US-9598503-B2 Methods and systems for polymer precipitation and generation of particles CERULEAN PHARMA INC. (US) 2017-03-21 US disclosed
US-9598503-B2 Methods and systems for polymer precipitation and generation of particles CERULEAN PHARMA INC. (US) 2017-03-21 US disclosed
US-9550860-B2 Cyclodextrin-based polymers for therapeutics delivery CERULEAN PHARMA INC. (US) 2017-01-24 US disclosed
US-9550860-B2 Cyclodextrin-based polymers for therapeutics delivery CERULEAN PHARMA INC. (US) 2017-01-24 US disclosed
US-20160082111-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CERULEAN PHARMA INC. (US) 2016-03-24 US disclosed
US-20160082111-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CERULEAN PHARMA INC. (US) 2016-03-24 US disclosed
US-20160058874-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CERULEAN PHARMA INC. (US) 2016-03-03 US disclosed
US-20160058874-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CERULEAN PHARMA INC. (US) 2016-03-03 US disclosed
US-20110178287-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CERULEAN PHARMA INC. 2011-07-21 US disclosed
US-20110152512-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY CERULEAN PHARMA INC. 2011-06-23 US disclosed
US-20110152512-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY CERULEAN PHARMA INC. 2011-06-23 US disclosed
WO-2011063421-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CERULEAN PHARMA INC. (US) 2011-05-26 WO disclosed
WO-2011031865-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CERULEAN PHARMA INC. (US) 2011-03-17 WO disclosed
EP-2277551-A2 Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto Cerulean Pharma Inc. (US) 2011-01-26 EP disclosed
US-20080058427-A1 Cyclodextrin-based polymers for therapeutics delivery INSERT THERAPEUTICS, INC. (US) 2008-03-06 US disclosed
US-20080058427-A1 Cyclodextrin-based polymers for therapeutics delivery INSERT THERAPEUTICS, INC. (US) 2008-03-06 US disclosed
US-7270808-B2 Having covalently coupled bioactive agent and targeting ligand; controlled release; stability, solubility; reduced toxicity INSERT THERAPEUTICS, INC. (US) 2007-09-18 US disclosed
US-7270808-B2 Having covalently coupled bioactive agent and targeting ligand; controlled release; stability, solubility; reduced toxicity INSERT THERAPEUTICS, INC. (US) 2007-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160082111-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY SDCBP, DDOST, DSC1 CYP2D6 2121/4885CYP2C19 2830/4885HIF1A 3095/4885
US-20080058427-A1 Cyclodextrin-based polymers for therapeutics delivery DDOST, DSC1, SI CYP2D6 2057/4885CYP2C19 2172/4885HIF1A 2570/4885
US-20160058874-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CDR2, DDOST, GALC CYP2D6 1989/4885CYP2C19 2796/4885HIF1A 4431/4885
US-20170369651-A1 CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO SDCBP, DDOST, CD47 CYP2D6 2585/4885CYP2C19 2930/4885HIF1A 2319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.